

CRO Oversight Benchmark Report

Survey of Leading Life Sciences Companies

Challenges & Best Practice in Continuous CRO Oversight


Respondents by Role



Over 100 ClinOps leaders from global life sciences companies responded to 50 questions in 3, 2016 ClinOps surveys.

Over half of the respondents outsource to three or more CROs.

Number of Trials



CRO oversight & collaboration has become imperative with the increasing growth of the clinical trials market.

FINDINGS-

In the next year:

- 90% plan to increase their use of CROs
- 100% anticipate process changes due to **pending** ICH E6 updates



resources to **CRO** oversight

"Why is CRO Oversight a Priority For Your Team?"

Less than 15%

#3






#2





believe they are efficient at CRO Oversight



Top 3 Metrics for CRO performance:




and resource of quality metrics and cycle time allocation (plan vs. actual)

#2 Issue resolution

CRO dashboard

Top priorities for a successful CRO relationship: data

Staff turnover



to quality data "What is the most common cause of a milestone delay from FPI to LPO?" 80 60

10%

transparency and real-time access

Data Clean Up Enrollment analysis Improve **speed and quality** with your CROs.



Clinical Intelligence: sponsors and CROs can now work from the same, accurate data in real-time and can manage ClinOps Insights

issues with defined escalation paths.